Pages that link to "Q37634350"

The following pages link to Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: Current status (Q37634350):

Displaying 36 items.

• Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis (Q24198072) (← links)
• Herbal medicines for the treatment of nonalcoholic steatohepatitis: current scenario and future prospects (Q26828615) (← links)
• Metformin in nonalcoholic steatohepatitis: a randomized controlled trial (Q33597395) (← links)
• An ErChen and YinChen Decoction Ameliorates High-Fat-Induced Nonalcoholic Steatohepatitis in Rats by Regulating JNK1 Signaling Pathway (Q33819857) (← links)
• Metabolic syndrome is linked to a mild elevation in liver aminotransferases in diabetic patients with undetectable non-alcoholic fatty liver disease by ultrasound (Q34331647) (← links)
• Effects of thiazolidinediones on polycystic ovary syndrome: a meta-analysis of randomized placebo-controlled trials (Q34397685) (← links)
• Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus (Q34620447) (← links)
• A study of standardized extracts of Picrorhiza kurroa Royle ex Benth in experimental nonalcoholic fatty liver disease (Q34921969) (← links)
• Effective Therapy Using Voglibose for Nonalcoholic Steatohepatitis in a Patient with Insufficient Dietary and Exercise Therapy: Exploring Other Treatment Possibilities (Q35071369) (← links)
• Metformin Prevents Tobacco Carcinogen–Induced Lung Tumorigenesis (Q35333423) (← links)
• Antioxidants as therapeutic agents for liver disease (Q35585469) (← links)
• A CONSORT-compliant, randomized, double-blind, placebo-controlled pilot trial of purified anthocyanin in patients with nonalcoholic fatty liver disease (Q36152941) (← links)
• Effects of a combination of puerarin, baicalin and berberine on the expression of proliferator-activated receptor-γ and insulin receptor in a rat model of nonalcoholic fatty liver disease (Q36502250) (← links)
• Histopathologic Evaluation of Nonalcoholic Fatty Liver Disease in Hypothyroidism-Induced Rats (Q36819364) (← links)
• Sex-Specific Association between Serum Uric Acid and Nonalcoholic Fatty Liver Disease in Type 2 Diabetic Patients (Q37038253) (← links)
• Patterns of use of insulin-sensitizing agents among diabetic, borderline diabetic and non-diabetic women in the National Health and Nutrition Examination Surveys (Q37169533) (← links)
• Nonalcoholic fatty liver disease and the coronary artery disease (Q37750546) (← links)
• Clinical syndromes and consequences of antiretroviral-related hepatotoxicity (Q37784777) (← links)
• Mitochondria and redox signaling in steatohepatitis (Q37815476) (← links)
• Review of approved pioglitazone combinations for type 2 diabetes (Q37884618) (← links)
• Expert opinion on current therapies for nonalcoholic fatty liver disease. (Q37884620) (← links)
• Potential approaches to ameliorate hepatic fat accumulation seen with MTP inhibition (Q38195808) (← links)
• Role of innate immune response in non-alcoholic Fatty liver disease: metabolic complications and therapeutic tools (Q38209324) (← links)
• Current pharmacotherapy for treating pediatric nonalcoholic fatty liver disease. (Q38249022) (← links)
• Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice (Q38328379) (← links)
• Treatment of nonalcoholic fatty liver disease: Where do we stand? an overview (Q38782562) (← links)
• Pharmacological management of nonalcoholic fatty liver disease in type 2 diabetes (Q39170225) (← links)
• Taurine and vitamin E supplementations have minimal effects on body composition, hepatic lipids, and blood hormone and metabolite concentrations in healthy Sprague Dawley rats (Q41882081) (← links)
• Synthesis and biological evaluation of novel urea- and guanidine-based derivatives for the treatment of obesity-related hepatic steatosis. (Q42802652) (← links)
• A novel mouse model of nonalcoholic steatohepatitis with significant insulin resistance (Q44372454) (← links)
• GLP-1-derived nonapeptide GLP-1(28–36)amide inhibits weight gain and attenuates diabetes and hepatic steatosis in diet-induced obese mice (Q47377801) (← links)
• Compound K attenuates glucose intolerance and hepatic steatosis through AMPK-dependent pathways in type 2 diabetic OLETF rats (Q51159954) (← links)
• α-Lipoic acid prevents mild portal endotoxaemia-induced hepatic inflammation and β cell dysfunction (Q51364683) (← links)
• Gemcabene downregulates inflammatory, lipid-altering and cell-signaling genes in the STAM™ model of NASH. (Q55358328) (← links)
• American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for Developing a Diabetes Mellitus Comprehensive Care Plan (Q83808238) (← links)
• Discordant effects on central obesity, hepatic insulin resistance, and alanine aminotransferase of low‐dose metformin and thiazolidinedione combination therapy in patients with impaired glucose tolerance (Q84666135) (← links)